Literature DB >> 31064848

Preexisting Commensal Dysbiosis Is a Host-Intrinsic Regulator of Tissue Inflammation and Tumor Cell Dissemination in Hormone Receptor-Positive Breast Cancer.

Claire Buchta Rosean1, Raegan R Bostic2, Joshua C M Ferey3, Tzu-Yu Feng1, Francesca N Azar1, Kenneth S Tung4, Mikhail G Dozmorov5, Ekaterina Smirnova5, Paula D Bos6, Melanie R Rutkowski7.   

Abstract

It is unknown why some patients with hormone receptor-positive (HR+) breast cancer present with more aggressive and invasive disease. Metastatic dissemination occurs early in disease and is facilitated by cross-talk between the tumor and tissue environment, suggesting that undefined host-intrinsic factors enhance early dissemination and the probability of developing metastatic disease. Here, we have identified commensal dysbiosis as a host-intrinsic factor associated with metastatic dissemination. Using a mouse model of HR+ mammary cancer, we demonstrate that a preestablished disruption of commensal homeostasis results in enhanced circulating tumor cells and subsequent dissemination to the tumor-draining lymph nodes and lungs. Commensal dysbiosis promoted early inflammation within the mammary gland that was sustained during HR+ mammary tumor progression. Furthermore, dysbiosis enhanced fibrosis and collagen deposition both systemically and locally within the tumor microenvironment and induced significant myeloid infiltration into the mammary gland and breast tumor. These effects were recapitulated both by directly targeting gut microbes using nonabsorbable antibiotics and by fecal microbiota transplantation of dysbiotic cecal contents, demonstrating the direct impact of gut dysbiosis on mammary tumor dissemination. This study identifies dysbiosis as a preexisting, host-intrinsic regulator of tissue inflammation, myeloid recruitment, fibrosis, and dissemination of tumor cells in HR+ breast cancer. SIGNIFICANCE: Identification of commensal dysbiosis as a host-intrinsic factor mediating evolution of metastatic breast cancer allows for development of interventions or diagnostic tools for patients at highest risk for developing metastatic disease.See related commentary by Ingman, p. 3539. ©2019 American Association for Cancer Research.

Entities:  

Mesh:

Year:  2019        PMID: 31064848      PMCID: PMC6983951          DOI: 10.1158/0008-5472.CAN-18-3464

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  49 in total

1.  Alterations in the Immune Cell Composition in Premalignant Breast Tissue that Precede Breast Cancer Development.

Authors:  Amy C Degnim; Tanya L Hoskin; Muhammad Arshad; Marlene H Frost; Stacey J Winham; Rushin A Brahmbhatt; Alvaro Pena; Jodi M Carter; Melody L Stallings-Mann; Linda M Murphy; Erin E Miller; Lori A Denison; Celine M Vachon; Keith L Knutson; Derek C Radisky; Daniel W Visscher
Journal:  Clin Cancer Res       Date:  2017-01-26       Impact factor: 12.531

2.  Systemic Correlates of White Adipose Tissue Inflammation in Early-Stage Breast Cancer.

Authors:  Neil M Iyengar; Xi Kathy Zhou; Ayca Gucalp; Patrick G Morris; Louise R Howe; Dilip D Giri; Monica Morrow; Hanhan Wang; Michael Pollak; Lee W Jones; Clifford A Hudis; Andrew J Dannenberg
Journal:  Clin Cancer Res       Date:  2015-12-28       Impact factor: 12.531

3.  Obesity promotes breast cancer by CCL2-mediated macrophage recruitment and angiogenesis.

Authors:  Lisa M Arendt; Jessica McCready; Patricia J Keller; Dana D Baker; Stephen P Naber; Victoria Seewaldt; Charlotte Kuperwasser
Journal:  Cancer Res       Date:  2013-08-19       Impact factor: 12.701

Review 4.  Antibiotic-Induced Changes in the Intestinal Microbiota and Disease.

Authors:  Simone Becattini; Ying Taur; Eric G Pamer
Journal:  Trends Mol Med       Date:  2016-05-10       Impact factor: 11.951

5.  Antibiotic-induced dysbiosis alters host-bacterial interactions and leads to colonic sensory and motor changes in mice.

Authors:  M Aguilera; M Cerdà-Cuéllar; V Martínez
Journal:  Gut Microbes       Date:  2015-01-20

Review 6.  The influence of the commensal microbiota on distal tumor-promoting inflammation.

Authors:  Claire M Buchta Rosean; Melanie R Rutkowski
Journal:  Semin Immunol       Date:  2017-07-04       Impact factor: 11.130

7.  Trametinib Drives T-cell-Dependent Control of KRAS-Mutated Tumors by Inhibiting Pathological Myelopoiesis.

Authors:  Michael J Allegrezza; Melanie R Rutkowski; Tom L Stephen; Nikolaos Svoronos; Alfredo Perales-Puchalt; Jenny M Nguyen; Kyle K Payne; Sunil Singhal; Evgeniy B Eruslanov; Julia Tchou; Jose R Conejo-Garcia
Journal:  Cancer Res       Date:  2016-11-01       Impact factor: 12.701

8.  Gut dysbiosis promotes M2 macrophage polarization and allergic airway inflammation via fungi-induced PGE₂.

Authors:  Yun-Gi Kim; Kankanam Gamage Sanath Udayanga; Naoya Totsuka; Jason B Weinberg; Gabriel Núñez; Akira Shibuya
Journal:  Cell Host Microbe       Date:  2014-01-15       Impact factor: 21.023

9.  Breast cancer statistics, 2017, racial disparity in mortality by state.

Authors:  Carol E DeSantis; Jiemin Ma; Ann Goding Sauer; Lisa A Newman; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2017-10-03       Impact factor: 508.702

10.  High mammographic density in women is associated with protumor inflammation.

Authors:  Cecilia W Huo; Prue Hill; Grace Chew; Paul J Neeson; Heloise Halse; Elizabeth D Williams; Michael A Henderson; Erik W Thompson; Kara L Britt
Journal:  Breast Cancer Res       Date:  2018-08-09       Impact factor: 6.466

View more
  40 in total

Review 1.  Demystifying the manipulation of host immunity, metabolism, and extraintestinal tumors by the gut microbiome.

Authors:  Ziying Zhang; Haosheng Tang; Peng Chen; Hui Xie; Yongguang Tao
Journal:  Signal Transduct Target Ther       Date:  2019-10-12

Review 2.  Redrawing therapeutic boundaries: microbiota and cancer.

Authors:  Jonathan Sholl; Gregory D Sepich-Poore; Rob Knight; Thomas Pradeu
Journal:  Trends Cancer       Date:  2021-11-26

3.  Slit2 Inhibits Breast Cancer Metastasis by Activating M1-Like Phagocytic and Antifibrotic Macrophages.

Authors:  Dinesh K Ahirwar; Ramesh K Ganju; Manish Charan; Sanjay Mishra; Ajeet K Verma; Konstantin Shilo; Bhuvaneswari Ramaswamy
Journal:  Cancer Res       Date:  2021-08-16       Impact factor: 13.312

4.  Sputum Microbiota in Coal Workers Diagnosed with Pneumoconiosis as Revealed by 16S rRNA Gene Sequencing.

Authors:  Vladimir G Druzhinin; Elizaveta D Baranova; Ludmila V Matskova; Pavel S Demenkov; Valentin P Volobaev; Varvara I Minina; Alexey V Larionov; Snezana A Paradnikova
Journal:  Life (Basel)       Date:  2022-06-02

5.  Aucubin Exerts Anticancer Activity in Breast Cancer and Regulates Intestinal Microbiota.

Authors:  Min Shao; Ziyun Kuang; Wenlin Wang; Shengnan Li; Guizhen Li; Yu Song; Haitao Li; Guozhen Cui; Hefeng Zhou
Journal:  Evid Based Complement Alternat Med       Date:  2022-05-16       Impact factor: 2.650

Review 6.  Gut Microbiota: Influence on Carcinogenesis and Modulation Strategies by Drug Delivery Systems to Improve Cancer Therapy.

Authors:  Runqi Zhu; Tianqun Lang; Wenlu Yan; Xiao Zhu; Xin Huang; Qi Yin; Yaping Li
Journal:  Adv Sci (Weinh)       Date:  2021-03-09       Impact factor: 16.806

Review 7.  The Life-Long Role of Nutrition on the Gut Microbiome and Gastrointestinal Disease.

Authors:  Joann Romano-Keeler; Jilei Zhang; Jun Sun
Journal:  Gastroenterol Clin North Am       Date:  2021-01-05       Impact factor: 3.806

Review 8.  The gut microbiota can be a potential regulator and treatment target of bone metastasis.

Authors:  Kelly F Contino; Hariom Yadav; Yusuke Shiozawa
Journal:  Biochem Pharmacol       Date:  2022-01-15       Impact factor: 5.858

Review 9.  Breast and gut microbiome in health and cancer.

Authors:  Jilei Zhang; Yinglin Xia; Jun Sun
Journal:  Genes Dis       Date:  2020-08-20

10.  Differential Expression of CD49a and CD49b Determines Localization and Function of Tumor-Infiltrating CD8+ T Cells.

Authors:  Marit M Melssen; Robin S Lindsay; Katarzyna Stasiak; Anthony B Rodriguez; Amanda M Briegel; Salwador Cyranowski; Melanie R Rutkowski; Mark R Conaway; Cornelis J M Melief; Sjoerd H van der Burg; Ukpong Eyo; Craig L Slingluff; Victor H Engelhard
Journal:  Cancer Immunol Res       Date:  2021-02-22       Impact factor: 12.020

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.